rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Alto Neuroscience, Inc.

ANRO · NYSE

Health CareBiotechnologyNot moving yetNeurotech

ANRO stood above a rising 150-day average in 48 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 12.1% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$3.6M
Officials’ trades on record
0
Institutions holding
197 (+8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 48 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$3.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 1
WhoDidSharesTraded
Nicholas Conrad SmithPRESIDENT AND CFOsold23,170at $25.7830 Sep 2026filed 1 Oct 2026
Nicholas Conrad SmithPRESIDENT AND CFOsold886at $26.8730 Sep 2026filed 1 Oct 2026
Nicholas Conrad SmithPRESIDENT AND CFOsold110,830at $26.5829 Sep 2026filed 1 Oct 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders197+8 on the quarter
New · exited34 · 25
Reported value$1.3B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20265,924,241$105.5M+1,572,149+36.1%
Alpha Wave Global, LPunchanged · filed 13 Aug 20263,707,757$97.8M00.0%
Point72 Asset Management, L.P.reduced · filed 14 Aug 20263,565,467$53.1M-119,449−3.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,084,193$58.7M+150,348+5.1%
ARMISTICE CAPITAL, LLCadded · filed 14 Aug 20263,062,000$51.4M+281,000+10.1%
Commodore Capital LPunchanged · filed 14 Aug 20262,723,196$71.9M00.0%
SYSTEMATIC FINANCIAL MANAGEMENT LPadded · filed 14 Aug 20262,640,214$34.3M+186,513+7.6%
ROYCE & ASSOCIATES LPadded · filed 14 Aug 20261,969,835$25.6M+440,884+28.8%
Broadfin Holdings LLCreduced · filed 14 Aug 20261,818,533$23.7M-250,800−12.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,698,857$31.2M+420,535+32.9%
31 Mar 2023 – 30 Jun 2026
120159198Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Nicholas Conrad Smith Company insiderPRESIDENT AND CFO · last 2 Oct 20262 · 2
Andrew Craig Miller Company insiderDirector · last 27 May 20260 · 0
Amit Etkin Company insiderPRESIDENT AND CEO · last 14 May 20261 · 0
Andrew Dreyfus Company insiderDirector · last 12 May 20260 · 0
Christopher Nixon Cox Company insiderDirector · last 12 May 20260 · 0
Gwill York Company insiderDirector · last 12 May 20260 · 0
Husseini Manji Company insiderDirector · last 12 May 20260 · 0
Ramiro Sanchez Company insiderDirector · last 12 May 20260 · 0
Adam Savitz Company insiderCHIEF MEDICAL OFFICER · last 11 Feb 20263 · 0
Michael Conick Hanley Jr. Company insiderCHIEF OPERATING OFFICER · last 11 Feb 20260 · 0
Maha Radhakrishnan Company insiderDirector · last 8 Mar 20240 · 0
Alpha Wave Global, Lp Company insider10% owner · last 6 Feb 20241 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-38.3%
Debt to equityFY 2025 · to 31 Dec 20250.11×
Share count trendFY 2025 · to 9 Mar 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$176.5M
Free cash flowFY 2025 · to 31 Dec 2025−$51.8M

Analyst forecasts

No analyst forecasts yet.